Veopoz™ (pozelimab-bbfg)
| Full Name | Veopoz™ (pozelimab-bbfg) |
| Drug | Veopoz |
| Manufacturer | Regeneron Pharmaceuticals |
| Route of Administration | Intravenous |
| Site of Care | Healthcare Facility |
| Approved Indication | The treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease |
| Disease | CD55-deficient protein-losing enteropathy (CHAPLE) Disease |
| Therapeutic Area | Allergy & Immunology, Genetics |
| Enrollment Form Link | Veopoz Enrollment Form |
| Phone Number | 800-438-2375 |
| Fax Number | 877-440-0891 |
| Product Website | veopoz.com |